These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1247 related items for PubMed ID: 2147780

  • 1. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons.
    Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ, Sibley DR.
    Science; 1990 Dec 07; 250(4986):1429-32. PubMed ID: 2147780
    [Abstract] [Full Text] [Related]

  • 2. Differential modulation of striatonigral dynorphin and enkephalin by dopamine receptor subtypes.
    Jiang HK, McGinty JF, Hong JS.
    Brain Res; 1990 Jan 15; 507(1):57-64. PubMed ID: 1967976
    [Abstract] [Full Text] [Related]

  • 3. D1 and D2 dopamine receptors differentially regulate c-fos expression in striatonigral and striatopallidal neurons.
    Robertson GS, Vincent SR, Fibiger HC.
    Neuroscience; 1992 Jul 15; 49(2):285-96. PubMed ID: 1359451
    [Abstract] [Full Text] [Related]

  • 4. Effects of D1 and D2 dopamine receptor stimulation on the activity of substantia nigra pars reticulata neurons in 6-hydroxydopamine lesioned rats: D1/D2 coactivation induces potentiated responses.
    Weick BG, Walters JR.
    Brain Res; 1987 Mar 10; 405(2):234-46. PubMed ID: 2952219
    [Abstract] [Full Text] [Related]

  • 5. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT, White FJ.
    Synapse; 1992 Mar 10; 10(3):206-16. PubMed ID: 1532677
    [Abstract] [Full Text] [Related]

  • 6. Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression.
    Carta AR, Frau L, Pinna A, Morelli M.
    Exp Neurol; 2010 Aug 10; 224(2):395-402. PubMed ID: 20452347
    [Abstract] [Full Text] [Related]

  • 7. D1-like and D2-like dopamine receptors synergistically activate rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease.
    Paul ML, Graybiel AM, David JC, Robertson HA.
    J Neurosci; 1992 Oct 10; 12(10):3729-42. PubMed ID: 1357113
    [Abstract] [Full Text] [Related]

  • 8. Differential effects of chronic dopamine D1 and D2 receptor agonists on rotational behavior and dopamine receptor binding.
    Engber TM, Marin C, Susel Z, Chase TN.
    Eur J Pharmacol; 1993 Jun 04; 236(3):385-93. PubMed ID: 8102970
    [Abstract] [Full Text] [Related]

  • 9. The effects of dopamine D-1 and D-2 receptor subtype agonists on nigrostriatal opioid dynorphin and enkephalin immunostaining in 6-hydroxydopamine lesioned rats.
    Jiang HK, Wang JY.
    Chin J Physiol; 1991 Jun 04; 34(4):413-25. PubMed ID: 1687937
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Electrophysiological effects of SKF 38393 in rats with reserpine treatment and 6-hydroxydopamine-induced nigrostriatal lesions reveal two types of plasticity in D1 dopamine receptor modulation of basal ganglia output.
    Huang KX, Walters JR.
    J Pharmacol Exp Ther; 1994 Dec 04; 271(3):1434-43. PubMed ID: 7996456
    [Abstract] [Full Text] [Related]

  • 12. N-methyl-D-aspartate receptor blockade differentially modifies regional cerebral metabolic responses to D1 and D2 dopamine agonists in rats with a unilateral 6-hydroxydopamine lesion.
    Engber TM, Anderson JJ, Boldry RC, Kuo S, Chase TN.
    Neuroscience; 1993 Jun 04; 54(4):1051-61. PubMed ID: 8101981
    [Abstract] [Full Text] [Related]

  • 13. Dopamine D2 receptor control of pallidal fos expression: comparisons between intact and 6-hydroxydopamine-treated hemispheres.
    Marshall JF, Cole BN, LaHoste GJ.
    Brain Res; 1993 Dec 31; 632(1-2):308-13. PubMed ID: 7908600
    [Abstract] [Full Text] [Related]

  • 14. Differential regulation of striatal preproenkephalin mRNA by D1 and D2 dopamine receptors.
    Pollack AE, Wooten GF.
    Brain Res Mol Brain Res; 1992 Jan 31; 12(1-3):111-9. PubMed ID: 1312196
    [Abstract] [Full Text] [Related]

  • 15. Dopamine receptor subtypes colocalize in rat striatonigral neurons.
    Surmeier DJ, Eberwine J, Wilson CJ, Cao Y, Stefani A, Kitai ST.
    Proc Natl Acad Sci U S A; 1992 Nov 01; 89(21):10178-82. PubMed ID: 1332033
    [Abstract] [Full Text] [Related]

  • 16. Lesions of the nigrostriatal dopamine projection increase the inhibitory effects of D1 and D2 dopamine agonists on caudate-putamen neurons and relieve D2 receptors from the necessity of D1 receptor stimulation.
    Hu XT, Wachtel SR, Galloway MP, White FJ.
    J Neurosci; 1990 Jul 01; 10(7):2318-29. PubMed ID: 1973947
    [Abstract] [Full Text] [Related]

  • 17. Role of the substantia nigra in the expression of dopamine D1 receptor-mediated and D2 receptor-mediated behaviours.
    Fletcher GH, Starr MS.
    Neuroscience; 1987 Dec 01; 23(3):1001-10. PubMed ID: 2963970
    [Abstract] [Full Text] [Related]

  • 18. 6-Hydroxydopamine lesions of rat substantia nigra up-regulate dopamine-induced phosphorylation of the cAMP-response element-binding protein in striatal neurons.
    Cole DG, Kobierski LA, Konradi C, Hyman SE.
    Proc Natl Acad Sci U S A; 1994 Sep 27; 91(20):9631-5. PubMed ID: 7937819
    [Abstract] [Full Text] [Related]

  • 19. Dopaminergic grafts in the striatum reduce D1 but not D2 receptor-mediated rotation in 6-OHDA-lesioned rats.
    Robertson GS, Fine A, Robertson HA.
    Brain Res; 1991 Jan 25; 539(2):304-11. PubMed ID: 1675908
    [Abstract] [Full Text] [Related]

  • 20. Neonatal and adult 6-hydroxydopamine-induced lesions differentially alter tachykinin and enkephalin gene expression.
    Sivam SP, Breese GR, Krause JE, Napier TC, Mueller RA, Hong JS.
    J Neurochem; 1987 Nov 25; 49(5):1623-33. PubMed ID: 2889804
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 63.